← All trials
NCT05871437
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Aug 31, 2025
- First posted
- May 23, 2023
- Last posted
- Sep 28, 2023
- Enrollment
- 379
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Fudan UniversityOverall official - principal investigator
- Fudan UniversityReponsible party - principal investigator
- LinkDoc Technology (Beijing) Co. Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.